On the Record · Nektar Therapeutics
Nektar Therapeutics competitors, on the record
The companies Nektar Therapeutics itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Nektar Therapeutics names
| Company | Named in |
|---|---|
| ImmunityBio, Inc. | 2025 |
| Regeneron | 2025 |
| TRexBio, Inc. | 2025 |
In its own words
ImmunityBio, Inc.
Word for word“For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include ImmunityBio, Inc., Nkarta Therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.).” 10-K for 2025
Regeneron
Word for word“In particular, we expect to compete with therapies that could be cytokine-based, microbiome-based, or toleragenic-based therapies (Regeneron, Leo Pharma, Eli Lilly and Company, Galderma, Symbiotix, LLC, Apogee Therapeutics, Janssen Pharmaceuticals, AstraZeneca and Tizona Therapeutics), regulatory T cell therapies (Sangamo Therapeutics, Inc., Quell Therapeutics, Ltd., Sonoma Biotherapeutics, Inc. GentiBio, Inc., Kyvema Therapeutics, Inc. and Tract Therapeutics, Inc.), or IL-2 based therapies (Sanofi SA (through its acquisition of Synthorx, Inc.)) or OX40/OX40L class (Sanofi SA).” 10-K for 2025
TRexBio, Inc.
Word for word“For NKTR-0165, we believe companies targeting the TNFR2 pathway for the treatment of patients with autoimmune disease include TRexBio, Inc. and Odyssey Therapeutics, Inc.” 10-K for 2025
Read from Nektar Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.